An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Clinical Therapeutics

Volumn 25, Issue 2, 2003, Pages 459-471

  Martin, Paul D ^a   Dane, Aaron L ^a   Schneck, Dennis W ^a   Warwick, Michael J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Drug interaction; Fenofibrate; HMG CoA reductase inhibitor; Pharmacokinetics; Rosuvastatin

Indexed keywords

FENOFIBRATE; FENOFIBRIC ACID; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; HEADACHE; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STEADY STATE; VOLUNTEER;

EID: 0037292311     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80089-9     Document Type: Article

References (22)

1. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl. 2002;2:33-36.
2. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-508.
3. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-275.
4. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk. 2001;8:383-390.
5. Nezasa K, Higaki K, Hasegawa H, et al. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis. 2000;151:39. Abstract MoP21:W6.
6. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab Dispos. 2002;30:1158-1163.
7. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler Suppl. 2001;2:90. Abstract P174.
8. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol. 2002;42:1116-1121.
9. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55:94-99.
10. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002;58:527-531.
11. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472-477.
12. McCormick AD, McKillop D, Butters CJ, et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol. 2000;40:1055. Abstract 46.
13. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol. 2000;40:1056. Abstract 48.
14. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269-276.
15. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155-162.
16. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:219-228.
17. Tucker GT, Houston JB, Huang SM. Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther. 2001;70:103-114.
18. Cooper KJ, Martin PD, Dane AL, et al. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. In press.
19. Michniewicz BM, Black AE, Sinz MW, Woolf TF. In vitro and in vivo metabolism of atorvastatin (CI-981). ISSX Proc. 1994;6:93. Abstract.
20. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997;25:1191-1199.
21. Jacobsen W, Kirchner G, Hallensleben K, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999;27:173-179.
22. Durrington P, Hamann A, Tuomilehto J, et al. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia. 2001;44(Suppl 1):A165 (631). Abstract.